It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

Eli Lilly and Company chief corporate brand officer Lina Polimeni described the new format as a “big evolution” in the ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Amgen didn't clarify whether the average weight reduction of up to about 20% was a placebo-adjusted figure. It most likely referred to total weight loss, which means the candidate probably isn't any ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Men at high risk of cardiovascular disease had brain volume changes a decade earlier than women, U.K. Biobank data showed.

Popular weight-loss drugs like Wegovy or Ozempic would be covered by Medicare or Medicaid under a newly-proposed rule by the ...